The Technical Analyst
Adverum Biotechnologies [ADVM]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Adverum Biotechnologies Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
1.70% $11.34
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 235.36 mill |
| EPS: | -11.60 |
| P/E: | -0.980 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 20.75 mill |
| Avg Daily Volume: | 0.273 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.980 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.17x |
| Company: PE -0.980 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.308 (-102.72%) $-11.65 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 9.51 - 13.17 ( +/- 16.16%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-10-03 | Seyedkazemi Setareh | Buy | 85 000 | Stock Option (Right to Buy) |
| 2023-10-03 | Soparkar Peter | Buy | 130 000 | Stock Option (Right to Buy) |
| 2023-10-03 | Fischer Laurent | Buy | 315 000 | Stock Option (Right to Buy) |
| 2024-02-12 | Seyedkazemi Setareh | Buy | 400 000 | Stock Option (Right to Buy) |
| 2024-02-12 | Fischer Laurent | Buy | 1 104 200 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 96.92 |
| Last 100 transactions |
| Buy: 14 665 896 | Sell: 1 551 540 |
Forecast:
16:00 - $11.34
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $11.34
Forecast 2: 16:00 - $11.34
Forecast 3: 16:00 - $11.34
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $11.34 (1.70% ) |
| Volume | 0.116 mill |
| Avg. Vol. | 0.273 mill |
| % of Avg. Vol | 42.29 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ADVM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 6 - 10:17 | buy | $1.959 | N/A | Active |
|---|
ADVM
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Latest Press Releases
2024-03-18 16:05:00 - Press Release
Adverum Biotechnologies Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Pipeline Highlights And Corporate Updates
- preliminary luna data presented at the annual meeting of the macula society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet amd -
2024-02-28 16:05:00 - Press Release
Adverum Biotechnologies To Participate In The Td Cowen 44th Annual Health Care Conference
Redwood city, calif., feb. 28, 2024 (globe newswire) -- adverum biotechnologies, inc. (nasdaq: advm), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that laurent fischer, m.d., president and chief executive officer of adverum biotechnologies, will participate in the ophthalmology corporate panel discussion at the td cowen 44th annual health care conference on tuesday, march 5th, 2024 at 9:10 a.m. et.
2024-02-12 08:00:00 - Press Release
Adverum Biotechnologies To Participate In The Oppenheimer 34th Annual Healthcare Life Sciences Conference
Redwood city, calif., feb. 12, 2024 (globe newswire) -- adverum biotechnologies, inc. (nasdaq: advm), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that laurent fischer, m.d., president and chief executive officer of adverum biotechnologies, will present at the oppenheimer 34th annual healthcare life sciences conference on tuesday, february 13th, 2024 at 12:00 p.m. et.
2024-02-08 07:00:00 - Press Release
Adverum Biotechnologies Announces Positive Preliminary Efficacy And Safety Data From Luna Phase 2 Trial Of Ixo-vec In Patients With Wet Amd
– both dose levels (2e11 & 6e10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
2024-02-05 07:45:00 - Press Release
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
- financing led by tcgx with participation from new and existing investors including 5am ventures, commodore capital, frazier life sciences, logos capital, samsara biocapital, venrock healthcare capital partners and vivo capital, as well two large investment management firms.
Latest News
2024-04-19 10:36:12 - Zacks Investment Research
Down -24.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
Adverum Biotechnologies (ADVM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2024-04-04 10:45:22 - Zacks Investment Research
Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?
Here is how Adverum Biotechnologies (ADVM) and Cigna (CI) have performed compared to their sector so far this year.
2024-04-04 09:36:03 - Zacks Investment Research
How Adverum (ADVM) Stock Stands Out in a Strong Industry
Adverum (ADVM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
2024-04-03 10:36:05 - Zacks Investment Research
Down -28.72% in 4 Weeks, Here's Why Adverum Biotechnologies (ADVM) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Adverum Biotechnologies (ADVM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2024-03-27 10:36:08 - Zacks Investment Research
Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
The heavy selling pressure might have exhausted for Adverum Biotechnologies (ADVM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2024-03-19 10:46:11 - Zacks Investment Research
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?
Here is how Adverum Biotechnologies (ADVM) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
2024-03-06 15:07:40 - InvestorPlace
Turn Pocket Change into Profit: 3 Penny Stocks Ready to Pop
There are plenty of penny stocks ready to pop. However, we have to remember that penny stocks are extremely risky, and can be costly in the end.
2024-02-27 06:10:00 - InvestorPlace
Stocks on the Launchpad: The Next 3 Market Sensations
In the current bullish stock market, it's an exhilarating period for savvy investors betting on the upcoming market sensations. The optimism is connected to the S&P 500 shattering the historic 5000 threshold, supported by the U.S. Federal Reserve's bullish projection of 2.9% growth in the first quarter (Q1).
2024-02-22 06:15:00 - InvestorPlace
Unleash Massive Returns With These 3 Top Penny Stocks
Despite a recent decline in the leading economic index, the U.S. economy is positioned for a positive future in 2024. Strong employment and robust stock levels contribute to the optimistic outlook.
2024-02-01 17:30:00 - GlobeNewsWire
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
- Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47 th Annual Meeting of the Macula Society, with company-sponsored webcast on Thursday, February 8, 2024 at 8:00am ET -